Preclinical Alzheimer's Disease: Definition, Natural History, and Diagnostic Criteria
Alzheimer’s & Dementia 12 (2016) 292-323 Perspective Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria Bruno Duboisa,*,1, Harald Hampela,b,1, Howard H. Feldmanc,1, Philip Scheltensd, Paul Aisene, Sandrine Andrieuf, Hovagim Bakardjiang, Habib Benalih, Lars Bertrami,j, Kaj Blennowk, Karl Broichl, Enrica Cavedob,m, Sebastian Crutchn, Jean-Franc¸ois Dartigueso, Charles Duyckaertsp,Stephane Epelbauma, Giovanni B. Frisoniq,r, Serge Gauthiers, Remy Genthont, Alida A. Gouwf,u, Marie-Odile Habertv,w, David M. Holtzmanx,y, Miia Kivipeltoz,aa, Simone Listab, Jose-Luis Molinuevoab,ac, Sid E. O’Bryantad, Gil D. Rabinoviciae, Christopher Roweaf, Stephen Sallowayag,ah,ai, Lon S. Schneideraj, Reisa Sperlingak,al, Marc Teichmanna, Maria C. Carrilloam, Jeffrey Cummingsan, Cliff R. Jack, Jr,ao; from the Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”; July 23, 2015; Washington DC, USA aInstitute of Memory and Alzheimer’s Disease (IM2A) and Brain and Spine Institute (ICM) UMR S 1127 Frontlab, Department of Neurology, AP_HP, Pitie-Salp^etriere University Hospital, Sorbonne Universities, Pierre et Marie Curie University, Paris 06, Paris, France B.D. serves as member of advisory board for Avid/Lilly, Roche, and Takeda, Lilly, Nutricia, Probiodrug, and EIP Pharma (paid to institution). Boehringer Ingelheim, and he receives research support from Amivid and He reports no conflicts with the present work. P.A. has served as a consul- Pfizer
[Show full text]